Terns Pharmaceuticals (TERN) Net Income towards Common Stockholders (2020 - 2023)
Historic Net Income towards Common Stockholders for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.1 million.
- Terns Pharmaceuticals' Net Income towards Common Stockholders fell 3127.45% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 4900.8%. This contributed to the annual value of -$89.6 million for FY2024, which is 78.76% up from last year.
- Per Terns Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$21.1 million for Q4 2023, which was down 3127.45% from -$29.8 million recorded in Q3 2023.
- Terns Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$9.2 million for Q1 2020, and its period low was -$29.8 million during Q3 2023.
- For the 4-year period, Terns Pharmaceuticals' Net Income towards Common Stockholders averaged around -$15.2 million, with its median value being -$13.9 million (2022).
- Per our database at Business Quant, Terns Pharmaceuticals' Net Income towards Common Stockholders tumbled by 210.51% in 2021 and then crashed by 7697.38% in 2023.
- Quarter analysis of 4 years shows Terns Pharmaceuticals' Net Income towards Common Stockholders stood at -$11.1 million in 2020, then fell by 29.0% to -$14.3 million in 2021, then decreased by 12.07% to -$16.1 million in 2022, then crashed by 31.27% to -$21.1 million in 2023.
- Its last three reported values are -$21.1 million in Q4 2023, -$29.8 million for Q3 2023, and -$17.9 million during Q2 2023.